Reference : Relationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Verte...
Scientific journals : Article
Human health sciences : Public health, health care sciences & services
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/130296
Relationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Vertebral Fracture Incidence in Patients Treated with Bazedoxifene
English
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Detilleux, Johann mailto [Université de Liège - ULg > Département de productions animales > Génétique quantitative >]
Chines, Arkadi []
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Sep-2012
Calcified Tissue International
Springer Verlag
91
4
244-9
Yes (verified by ORBi)
International
0171-967X
New York
NY
[en] Bone turnover marker ; DEXA ; Fracture ; Bazedoxifene
[en] We analyzed the relationships between bone
mineral density (BMD) or bone turnover marker (BTM)
changes and vertebral fracture incidence in women treated
with bazedoxifene using a post hoc analysis from a 3-year
randomized, placebo-controlled study evaluating the effect
of bazedoxifene (20 or 40 mg) on fracture risk reduction.
BMD was assessed at baseline and every 6 months for
3 years. Osteocalcin and C-telopeptide of type I collagen
were assessed at baseline and at 3, 12, and 36 months.
Vertebral fractures were assessed with a semiquantitative
visual assessment. Data were available for 5,244 women, of
whom 3,476 were treated with bazedoxifene. Using a
logistic regression analysis and the classical Li approach,
the proportion of fracture incidence explained by BMD
change after 3 years of bazedoxifene treatment was 29 %
for the total hip and 44 % for the femoral neck. The proportion
of treatment explained by lumbar BMD change
could not be quantified accurately because of the significant
interaction between treatment and change in BMD. With
the same model, the 12-month BTM changes explained up
to 29 % of the fracture risk reduction observed with the two
forms of bazedoxifene. In women treated with bazedoxifene,
changes in femoral neck BMD, hip BMD, or BTMs
explained a moderate proportion of the fracture risk
reduction observed during the 3 years of follow-up. However,
BMD or BTM changes cannot be recommended for
individual monitoring of women treated with bazedoxifene.
http://hdl.handle.net/2268/130296
10.1007/s00223-012-9629-y

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence ....pdfPublisher postprint168.34 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.